If you've experienced a stroke due to a blood clot, AGGRENOX may help lower the risk of a subsequent stroke.
During a 24-month clinical study with patients who have had a TIA (transient ischemic attack or "mini-stroke") or stroke due to blood clot, over 90% of patients on AGGRENOX (1493 patients our of a total of 1650) remained free of recurrent stroke. Click here for Important Safety Information.
Read about the clinical study behind AGGRENOX.
This flash element is not visible because you do not have Adobe® Flash Player 9. Click here to download the latest version free of charge. This link is provided to you as a convenience. Boehringer Ingelheim Pharmaceuticals, Inc. does not control, and is not responsible for, the content of any linked page.

The information you submitted cannot be captured at this time due to routine maintenance on the website. Please try back later. We are sorry for the inconvenience.